

## PERSONAL INFORMATION

Hedvig Marie Egeland Nordeng

## WORK EXPERIENCE

- 
- January 2011- Present **Professor and Head of the PharmacoEpidemiology and Drug Safety (PharmaSafe) Research Group**  
University of Oslo (Norway)  
[www.mn.uio.no/farmasi/english/research/groups/pharma-safe/](http://www.mn.uio.no/farmasi/english/research/groups/pharma-safe/) School of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo
- January 2015- Present **Head of the PharmaTox Strategic Research Initiative**  
University of Oslo (Norway)  
Faculty of Mathematics and Natural Sciences, University of Oslo  
[www.mn.uio.no/farmasi/english/research/groups/pharmatox/](http://www.mn.uio.no/farmasi/english/research/groups/pharmatox/)
- January 2015- Present **Head of the Norwegian PhD School of Pharmacy**  
University of Oslo (Norway)  
<https://www.mn.uio.no/farmasi/english/research/norwegian-phd-school/>  
[www.mn.uio.no/farmasi/english/research/norwegian-phd-school/](http://www.mn.uio.no/farmasi/english/research/norwegian-phd-school/)
- January 2006- Present **Senior researcher (20%)**  
The Norwegian Institute of Public Health (NIPH) (Norway)  
Department of Child Health and Development
- January 2005-December 2007 **Post doctoral position, Drug Safety in Pregnancy**  
University of Oslo (Norway)  
Drug Safety in Pregnancy. Dpt. of Pharmacotherapy, Faculty of Medicine, University of Oslo, Norway
- January 2005-December 2005 **Drug information specialist (part time)**  
Regional Drug Information Centre, Rikshospitalet hospital (Norway)

## EDUCATION AND TRAINING

- 
- January 1999-December 2004 **PhD in Pharmacoepidemiology**  
University of Oslo (Norway)
- January 1992-December 1997 **M.Sc. and B.Sc. in Pharmacy**  
University of Oslo (Norway)
- January 1987-December 1992 **Baccalauréat Française**  
Lycée Edouard Herriot, Lyon (France)

## ADDITIONAL INFORMATION

**Expertise** My research experience and expertise is in <strong>perinatal pharmacoepidemiology and pharmacotherapy.</strong>In 2015, I was awarded an <strong>ERC StG</strong> with the project <strong>DrugsInPregnancy.</strong> This enabled me to focus on study on long-term reproductive safety of medications. The ERC project led to novel insight on neurodevelopmental outcomes for prenatal exposure to medications including antidepressants and analgesics. In 2015, I established the <strong>PharmaTox Strategic Research Initiative</strong>, selected and funded by UiO as a priority research environment. It enabled me to unite researchers in bioinformatics, statistics, geneticists and neurotoxicity to generate novel insight on effects of pharmaceuticals on human neurotoxicity and neurodevelopment. I have designed new training courses within pharmacoepidemiology at the masters and doctoral levels. I have also served on national committees to develop competencies for doctoral training in pharmaceutical sciences, currently as head the Norwegian PhD School in Pharmaceutical sciences with more than 100 PhD students and supervisors. I have had a close collaboration with Nordic partners in research and education through the <strong>Nordic Pharmacoepidemiology Network (NorPEN)</strong> where I currently serve on the Executive Committee member. In 2018, I hosted the 11<sup>th</sup> NorPEN meeting in Oslo at UiO.

**Publications** Summary I have in total 157 published publications. My overall H-index is 32 according to ISI Web of Knowledge. The total number of citations excl. self-citations is 3397. <br /><br />Selected publications:<strong><u>A. Introducing advanced methods to Perinatal pharmacoepidemiology.</u></strong><strong>1) </strong>Stoltenberg EA\*, <strong>Nordeng HM</strong>, Ystrom E, Samuelsen SO. The cure model in perinatal epidemiology. Stat Methods Med Res. 2020 Feb 11:962280220904092.<strong>2) </strong>Lupattelli A, Wood ME, <strong>Nordeng H.</strong> Analyzing Missing Data in Perinatal Pharmacoepidemiology Research: Methodological Considerations to Limit the Risk of Bias. Clin Ther. 2019 Dec;41(12):2477-2487.<strong>3) </strong>Cohen JM, Wood ME\*, Hernández-Díaz S, Ystrom E, <strong>Nordeng</strong><strong> H.</strong> Paternal antidepressant use as a negative control for maternal use: assessing familial confounding on gestational length and anxiety traits in offspring. Int J Epidemiol. 2019; 48: 1665-1672. PMID: 31369122.<strong>4) </strong>Wood ME\*, Lapane KL, van Gelder MMHJ, Rai D, <strong>Nordeng HME</strong>. <a href="https://www.ncbi.nlm.nih.gov/pubmed/29044735" rel="nofollow">Making fair comparisons in pregnancy medication safety studies: An overview of advanced methods for confounding control.</a> Pharmacoepidemiol Drug Saf. 2018; 27: 140-147.<strong><u>B. Expanding the focus: Medication Safety in Pregnancy</u></strong><strong>5) </strong>Lupattelli A, Wood M, Lapane K, Spigset O, <strong>Nordeng H.</strong> Risk of preeclampsia after gestational exposure to selective serotonin reuptake inhibitors and other antidepressants: A study from The Norwegian Mother and Child Cohort Study. Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1266-1276.<strong> </strong><strong>6) </strong>Frank AS\*, Lupattelli A\*, Brandlistuen RE\*, <strong>Nordeng H.</strong> Maternal Thyroid Hormone Replacement Therapy Exposure and Language and Communication Skills of Offspring at 8 Years of Age. JAMA Netw Open. 2019;2: e1912424. PMID: PMC6777253.<strong>7) </strong>Ystrom E, Gustavson K, Brandlistuen RE\*, Knudsen GP, Magnus P, Susser E, Davey Smith G, Stoltenberg C, Suren P, Haberg SE, Hornig M, Lipkin WI, <strong>Nordeng H,</strong> Reichborn-Kjennerud T. Prenatal Exposure to Acetaminophen and Risk of ADHD. Pediatrics 2017; 140.<strong>8) </strong>Gervin K\*, <strong>Nordeng H,</strong> Ystrom E, Reichborn-Kjennerud T, Lyle R. Long-term prenatal exposure to paracetamol is associated with DNA methylation differences in children diagnosed with ADHD. Clin Epigenetics. 2017; 9: 77. PMID: PMC5540511.<strong>9) </strong>Gervin K, et al. Cell type specific DNA methylation in cord blood: A 450K-reference data set and cell count-based validation of estimated cell type composition. Epigenetics. 2016;11:690-698.<strong><u>C. Start-of-the art review and leadership</u></strong><strong>10) </strong>Amundsen S\*, <strong>Nordeng H,</strong> Nežvalová-Henriksen K\*, Stovner LJ, Spigset O. Pharmacological treatment of migraine during pregnancy and breastfeeding. Nature Review Neurology 2015; 11: 209-19.<strong>11) </strong>Nordeng H</strong>, Lupattelli A, Wood M. Prenatal exposure to

antidepressants and increased risk of psychiatric disorders. BMJ. 2017 Sep 6;358:j3950. doi: 10.1136/bmj.j3950

**Projects** MAJOR GRANTS:2020 - 2022 EU-COVID-19 Project leader NFR (4.97 M NOK)2015 - 2020 DrugsInPregnancy (STG GA No. 639377) Project leader ERC (1.5 M EUR)2019 - 2024 ConcePTION Partner, task lead 1.5 IMI H2020 (13 M EUR Total, 52 partners).2019 - 2023 PharmaTox 2.0 Project leader UiO MN, Strategic Research Initiative (0.9 M EUR)2015 - 2020 PharmaTox 1.0 Project leader UiO MN, Strategic Research Initiative (1.8 M EUR)2015 - 2020 The PharmaTox Honours Program in Quantitative Life Sciences Project leader RCN, INTPART Inter-national partnerships (440 k EUR)2012 - 2016 Grants for 1 post doc and 2 PhD positions from non-profit organizations Extrastiftelsen & Sanitetskvinnene

**Memberships** MEMBERSHIPS OF SCIENTIFIC SOCIETIES:<br />- European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (EnCePP)<br />- International Society of Pharmacoepidemiology (ISPE), FISPE<br />- European Drug Utilization Research Group (EuroDRUG)<br />- Organization of Teratology Information Specialists (OTIS)<br />- European Network of Teratology Information Specialists (ENTIS)<br />- Nordic Pharmacoepidemiology Network (NorPEN<em>)<br />- </em>COST network; Research Network in Peripartum Depression Disorder <em>(national contact person for Norway)</em>

**Other Relevant Information**